Drugs / USL311
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02765165 | Apr 2016 → Jul 2020 | glioblastoma | Proximagen Limited | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | USL311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02765165 ↗ |
| Modality | Small molecule | — CHEMBL4297449 ↗ |
| Route | Intravenous | “USL311, intravenous, once per week, starting at 60 mg/m˄2” NCT02765165 ↗ |